ATAI News and Press, ATAI Life Sciences N.V. From 09/01/23

2023-09-01 19:02:09 ET Summary Atai Life Sciences is advancing RL-007 for the treatment of cognitive impairment associated with schizophrenia, with top-line results expected in the 2nd half of 2024. The company is also working on advancing COMP360 for treatment-resistant depressio...

2023-08-31 12:35:49 ET More on psychedelic drugmakers Compass Pathways: Debt Deal Secured, Cash Runway Extended COMPASS Pathways plc ( CMPS ) Q2 2023 Earnings Call Transcript Mind Medicine Inc. ( MNMD ) Q2 2023 Earnings Call Transcript Psychedelic Sto...

Psychedelics have the potential to revolutionize psychiatry by significantly improving treatment outcomes and safety while minimizing side effects. A plethora of studies have revealed that hallucinogenic compounds such as psilocybin can be especially effective when combined with talk therapy, p...

Psychedelics are poised to transform mental health and the psychiatry industry in major ways. A recent surge of psychedelic-related research and clinical trials has revealed that the federally controlled drug may have prolific mental health benefits, especially against conditions that don...

A panel of expert authors is calling on authorities to facilitate the study of psychedelic compounds as cancer distress treatments . In a paper published in the “International Journal of Gynecological Cancer ,” the authors noted that women with late-stage gynecologic tumors often ...

2023-08-22 12:50:11 ET More on psychedelic drug companies Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets. COMPASS: The Landscape Is Changing Quickly; Risk Is Up And Potential Down Psychedelic Stocks: Don't Bet On Just 1 Company Seelos:...

The American Psychedelic Practitioners Association (APPA) and nonprofit BrainFutures have teamed up to publish the first-ever guidelines for psychedelic-assisted therapists. These new guidelines will establish standards for the relatively new field of psychedelic-assisted therapy as the segment...

2023-08-10 11:01:09 ET ATAI Life Sciences press release ( NASDAQ: ATAI ): Q2 GAAP EPS of -$0.21 in-line. Cash, cash equivalents and short-term investments totaled $227.5 million as of June 30, 2023, compared to $273.1 million as of December 31, 2022. For further deta...

Advanced multiple clinical stage assets in development, including the on-going Phase 2b study of RL-007 in patients with Cognitive Impairment Associated with Schizophrenia DMX-1002 (Ibogaine) Phase 1 results enable discussions with regulatory authorities to assess progressing into proof...

NEW YORK and BERLIN, Aug. 08, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced results from Perception Neuroscience’s Phase 1 intravenou...